Navigation Links
Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck
Date:7/24/2009

KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported a proposed settlement, subject to Court approval, to resolve litigation seeking to enjoin the planned merger with Merck & Co., Inc., and other forms of relief. The consolidated class action lawsuits, previously reported in the merger proxy statement/prospectus filed June 25, 2009, were filed in U.S. District Court for the District of New Jersey.

The proposed settlement, as more fully described in a Form 8-K being filed today, provides for Schering-Plough to make additional disclosures related to the proposed merger, which are contained in the Form 8-K. No damages would be paid by Schering-Plough in connection with this proposed settlement. The parties agreed that plaintiffs' counsel may apply to the Court for an award of attorneys' fees and costs, to be paid by Schering-Plough.

This settlement, if approved by the court, and the settlement announced by Merck today, will serve to resolve and release all claims that were or could have been brought by any shareholder of Schering-Plough or Merck challenging any aspect of the proposed merger, including any disclosures made in connection therewith. Schering-Plough said the proposed settlement is not in any way an admission of any wrongdoing or liability in connection with plaintiffs' allegations. The company said it agreed to settle the suit in order to avoid the further costs and inherent uncertainty of litigation.

Schering-Plough Disclosure Statement

This communication includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the resolution of liti
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus
2. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
3. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
4. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
5. Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males
6. Schering-Plough Starts Patient Enrollment in Phase 3 Trial for Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
7. Schering-Plough Flips the Switch on 1.7 MW Rooftop Solar Panel System, One of the Largest in N.J., North America
8. J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards
9. Schering-Plough Reports Financial Results for 2009 First Quarter
10. EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year
11. Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 Brain not ... DC, MS, explains why such seemingly minor brain problems ... concussions are vital red flags. They indicate the brain ... multiple sclerosis (MS), Alzheimer’s, Parkinson’s, stroke, and other neurological ... in June 2013 by Elephant Press is now available ...
(Date:6/19/2013)... June 19, 2013 Chrysler made news recently ... recall of 2.7 million Jeeps. The Jeep models in question ... Liberty, which according to the NHTSA are vulnerable to fire ... in these models are rear-mounted and have been alleged to ... show the Grand Cherokee with 32 rear-end crashes, which resulted ...
(Date:6/19/2013)... 2013 Citi Bike has come to New York ... David Perna to know for sure how many patients will choose ... they’ll have the option. In fact, he’s happy about anything ... also make it more convenient for them to visit his office ... of Complimentary Alternative Medicine at Back and Body Medical and an ...
(Date:6/19/2013)... The Journal of Parasitology – Although altering or ... creates questions of ethics. For scientific publications, it could ... case shows, scientific publications need clear guidelines for acceptable ... Parasitology features a commentary on a case ... in the Journal of the New York Entomological Society. ...
(Date:6/19/2013)... (June 19, 2013) In what is believed to ... most common form of hereditary dystonia a movement ... in deep brain stimulation report good success rates and ... the Movement Disorders Program at Cedars-Sinai Medical Center,s Department ... the Division of Neurosurgery at Beth Israel Deaconess Medical ...
Breaking Medicine News(10 mins):Health News:Brain Not Working? Minor Symptoms Now Could Mean MS, Alzheimer's, or Parkinson's Later 2Health News:Brain Not Working? Minor Symptoms Now Could Mean MS, Alzheimer's, or Parkinson's Later 3Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2
... Md. (Sept. 28, 2011) Women generally have a lower ... most of their adult lives, with lower rates of high ... ("good") cholesterol and lower levels of LDL ("bad") cholesterol. Then ... pressure at a greater rate than men and their cholesterol ...
... For a variety of reasons it is important to be ... Farm animals have generally been marked by branding with ... cats are being uniquely identified by the implant of a ... countries are now moving towards the use of microchips. ...
... Spanish . , Scientists at the University of ... and zinc in pregnant women may be a factor associated with ... and which had never been proven in humans before. For ... tests. From these 265 women, 132 had suffered a spontaneous miscarriage ...
... HIV in a way that makes it no longer able ... a report published online September 19 in the journal ... development and lead to new treatments. "Something about the ... it, making it a tough target for vaccine development," says ...
... (HealthDay News) -- The drinking habits of the friends of ... the youngster,s drinking than the habits of the teen,s own ... researchers who analyzed national data collected from 449 heterosexual couples ... The study appears in the October issue of the ...
... San Diego, CA, September 28, 2011 If future ... of patients and their communities, medical education must put ... in a supplement to October,s American Journal of ... than 30 research papers and commentaries authored by top ...
Cached Medicine News:Health News:Physiology of cardiovascular disease: Gender disparities 2Health News:The mark of the beast: tradition or stress? 2Health News:Low zinc and copper levels might cause spontaneous abortion 2Health News:Low zinc and copper levels might cause spontaneous abortion 3Health News:Hide-and-seek: Altered HIV can't evade immune system 2Health News:Teen Drinking Most Influenced by Friends of Friends: Study 2Health News:Medical education needs more of a public health and prevention focus 2
(Date:6/19/2013)... CARLSBAD, Calif. , June 19, 2013 /PRNewswire/ ... ) today announces a licensing agreement granting Suzhou ... develop and manufacture siRNA therapeutics in ... technology.  Ribo will formulate proprietary siRNA molecules in ... platform designed to address human diseases with high ...
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
(Date:6/19/2013)... INDIANAPOLIS , 19. Juni 2013 ... bekannt, dass mit der Entwicklung von ... bahnbrechender Schritt in der Beschichtung mit ... die Vorteile von biokompatiblem Parylene mit ... effektive Beseitigung schädlicher Mikroorganismen auf beschichteten ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a 92 ... treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical studies,recently ...
... Groundbreaking 2002 ... ... study reveals that,coiling, a minimally invasive procedure to treat aneurysms in ... treatment in those aneurysms considered "untouchable" by the,traditional surgical option. One ...
Cached Medicine Technology:PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 3
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: